AcroCyte Therapeutics, San Carlos, CA, Onsite
AcroCyte Therapeutics is closing the gap between laboratory models and patient-specific medicine. Our core technology, the R³CE® platform, is an easy-to-use, FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens—like circulating tumor cells, needle biopsies and frozen tissues—into functional 3D organoids in days. This breakthrough powers our commercial Onco-REAL™ clinical service, which provides comprehensive functional analysis from liquid biopsies for timely oncology decisions, while our autologous cell therapy pipeline aims to transform a patient’s own cells into curative solutions. We empower academic, clinical, and industry partners worldwide to leverage the R³CE® platform for novel drug discovery, diagnostics, and regenerative medicine, providing a foundational technology limited only by imagination. AcroCyte is driving a revolution to make these advanced platforms a routine part of clinical practice—accessible, affordable, and impactful for patients worldwide.
We are seeking a highly motivated and experienced scientist to lead our NGS and genomics capabilities in a fast-paced startup environment. This role sits at the interface of molecular biology, bioinformatics, and translational research, and will play a critical role in shaping experimental strategy, platform development, and data-driven decision-making.
As a Senior/Principal Scientist, you will own end-to-end sequencing workflows, from experimental design through data interpretation, and apply these insights to advance next-generation therapies and platform technologies. This is a high-impact, hands-on role requiring both deep technical expertise and the ability to operate independently with minimal structure.
This is a full-time position at AcroCyte Therapeutics in San Carlos, CA.
AcroCyte Therapeutics is closing the gap between laboratory models and patient-specific medicine. Our core technology, the R³CE® platform, is an easy-to-use, FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens—like circulating tumor cells, needle biopsies and frozen tissues—into functional 3D organoids in days. This breakthrough powers our commercial Onco-REAL™ clinical service, which provides comprehensive functional analysis from liquid biopsies for timely oncology decisions, while our autologous cell therapy pipeline aims to transform a patient’s own cells into curative solutions. We empower academic, clinical, and industry partners worldwide to leverage the R³CE® platform for novel drug discovery, diagnostics, and regenerative medicine, providing a foundational technology limited only by imagination. AcroCyte is driving a revolution to make these advanced platforms a routine part of clinical practice—accessible, affordable, and impactful for patients worldwide.
View company profile →